

Please amend the subject application as follows:

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application:

**Listing of the claims:**

- 1.-15. (Cancelled)
16. (Previously Presented) Hybridoma cell line, designated OD-3, having ATCC accession number HB 10204.
17. (Previously Presented) Hybridoma cell line, designated NB-3, having ATCC accession number HB 10205.
18. (Previously Presented) Hybridoma cell line, designated TA-1, having ATCC accession number HB 10206.
19. (Previously Presented) Monoclonal antibody produced by the hybridoma cell line of claim 16.
20. (Previously Presented) Monoclonal antibody produced by the hybridoma cell line of claim 17.

Applicants: Walter P. Carney et al.

U.S. Serial No.: 08/488,180

Filed: June 7, 1995

Page 3

21. (Previously Presented) Monoclonal antibody produced by the hybridoma cell line of claim 18.

22. (Previously Presented) An immunoreactive fragment of the monoclonal antibody of claim 19.

23. (Previously Presented) An immunoreactive fragment of the monoclonal antibody of claim 20.

24. (Previously Presented) An immunoreactive fragment of the monoclonal antibody of claim 21.

25.-27. (Cancelled)